Literature DB >> 17430685

Use of progression-free survival as a valid endpoint in phase II cancer clinical trials.

Maurie Markman1.   

Abstract

Entities:  

Mesh：

Year:  2007        PMID： 17430685     DOI： 10.1007/s11912-007-0015-2

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN： 1523-3790            Impact factor:   5.075


× No keyword cloud information.
  8 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

2.  Viewing ovarian cancer as a "chronic disease": what exactly does this mean?

Authors:  Maurie Markman
Journal:  Gynecol Oncol       Date:  2005-10-14       Impact factor: 5.482

3.  Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens.

Authors:  Mohammad I Zia; Lillian L Siu; Greg R Pond; Eric X Chen
Journal:  J Clin Oncol       Date:  2005-10-01       Impact factor: 44.544

4.  The importance of distinguishing "clinical judgement" in cancer management from "selection bias" in clinical trials.

Authors:  M Markman
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

5.  Progression-free survival rate as primary end point for phase II cancer clinical trials: application to mesothelioma--The EORTC Lung Cancer Group.

Authors:  Julie Francart; Catherine Legrand; Richard Sylvester; Martine Van Glabbeke; Jan P van Meerbeeck; Annie Robert
Journal:  J Clin Oncol       Date:  2006-07-01       Impact factor: 44.544

6.  Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.

Authors:  Russell J Schilder; Michael W Sill; Xiaowei Chen; Kathleen M Darcy; Steven L Decesare; George Lewandowski; Roger B Lee; Cletus A Arciero; Hong Wu; Andrew K Godwin
Journal:  Clin Cancer Res       Date:  2005-08-01       Impact factor: 12.531

7.  A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.

Authors:  James C Yang; Leah Haworth; Richard M Sherry; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Seth M Steinberg; Helen X Chen; Steven A Rosenberg
Journal:  N Engl J Med       Date:  2003-07-31       Impact factor: 91.245

8.  Is patient travel distance associated with survival on phase II clinical trials in oncology?

Authors:  Elizabeth B Lamont; Davinder Hayreh; Kate E Pickett; James J Dignam; Marcy A List; Kerstin M Stenson; Daniel J Haraf; Bruce E Brockstein; Sarah A Sellergren; Everett E Vokes
Journal:  J Natl Cancer Inst       Date:  2003-09-17       Impact factor: 13.506
  8 in total
  1 in total

1.  Using short-term response information to facilitate adaptive randomization for survival clinical trials.

Authors:  Xuelin Huang; Jing Ning; Yisheng Li; Elihu Estey; Jean-Pierre Issa; Donald A Berry
Journal:  Stat Med       Date:  2009-05-30       Impact factor: 2.373
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.